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During photodynamic therapy (PDT), illumination of the 
skin surface leads to the excitation of protoporphyrin IX 
(PpIX). As PpIX returns to its basic energetic state, reac-
tive oxygen radicals are generated, inducing the apoptosis 
of tumour cells (1). PDT is currently regarded as the 
first-line treatment for actinic keratosis (AK), superficial 
basal cell carcinoma (BCC) and Bowen’s disease (BD) 
(2). Therapy-related pain is the most frequent side-effect. 
Patients usually report a cumulative burning sensation 
during illumination, which becomes intense within a few 
minutes of the start of the procedure. In some cases, pain 
can be so severe that the illumination must be stopped 
prematurely, resulting in insufficient PpIX formation and 
inadequate therapeutic result. The aim of our study was to 
evaluate the degree of treatment-associated pain during 
PDT with two different photosensitizers, 5-aminolaevu-
linic acid (ALA) and methyl aminolaevulinate (MAL), 
in different anatomical regions.
PATIENTS AND METHODS
PDT was performed on 182 occasions to treat non-melanoma skin 
cancer (80 occasions for AK, 97 for BCC and 5 for BD). Eighty-
seven patients were involved (32 females, 55 males, mean age 72 
years, age range 43–92 years). The locations of the tumours were 
as follows: head and neck region: 111 (cheeks: 22, forehead: 31, 
temporal area: 12, nose: 18, auricular region: 12, lip: 1, scalp: 
11, neck: 4), trunk: 45 (back: 29, chest: 15, abdomen: 1), and 
extremities: 26 (shoulders: 13, arms: 6, hands: 5, shin: 1, thigh: 
1). Patients were randomly assigned to receive either 20% ALA 
or 16% MAL ointment for 4 h in an occlusive dressing. ALA was 
used for 103 treatments (48 patients, 18 females, 30 males, age 
range 46–92 years, mean age 72 years) and MAL for 79 treat-
ments (39 patients, 14 females, 25 males, age range 43–87 years, 
mean age 70.4 years). After 4 h of photosensitizing, the dressing 
was removed. Thirty minutes prior to illumination, patients were 
offered, and if requested, administered 500 mg paracetamol orally 
for pain relief. Illumination was performed with 630-nm visible 
red light at a dose of 37 J/cm2, using a monochromatic diode 
lamp (Aktilite®, PhotoCure ASA, Oslo, Norway). The degree of 
patient-reported pain was assessed immediately after PDT on a 
0–10 numeric rating scale (NRS), where 0 = no pain, and 10 = un-
bearable pain. One and two-way analysis of variance (ANOVA), 
Student’s t-test and the Scheffe test (post hoc), were applied for 
statistical analysis with Statistica 8.0 software (StatSoft Inc.). 
Differences were considered statistically significant at p < 0.05. 
Four weeks after the first treatment, a follow-up examination 
was performed. Therapeutic results were characterized as one of 
the three categories: complete remission, incomplete remission, 
or no response.
RESULTS
Ten patients with a total of 24 treatments experienced 
intolerable pain, necessitating premature discontinua-
tion of the treatment. In 21 of these incomplete treat-
ments, the photosensitizer used was ALA.
The levels of pain in the regions of the head, trunk 
and extremities during PDT were compared between 
the groups receiving the different photosensitizers, ALA 
and MAL. In the head region, MAL-PDT caused signifi-
cantly less pain than did ALA-PDT (two-way ANOVA, 
Scheffe post hoc test, p1 = 0.00068). The level of pain 
during PDT of AKs was significantly greater than that 
in the case of BCCs (two-way t-test, p = 0.0025). In 
the BCC and AK groups, significant differences were 
detected between MAL and ALA (Fig. 1).
There was no significant difference in the degree of 
pain between the genders (two-way t-test, p = 0.19). In-
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Fig. 1. Comparison methyl aminolaevulinate (MAL)- and 5-aminolaevulinic 
acid (ALA)-photodynamic therapy (PDT)-associated pain in patients with 
actinic keratosis (AK) and basal cell carcinoma (BCC) (mean numeric rating 
scale (NRS) values with standard deviation (SD) bars). Pain during BCC 
treatment was lower in both the ALA and MAL groups; however, only reached 
statistical significance in the MAL group (two-way analysis of variance 
(ANOVA), p = 0.0025, Scheffe post hoc test, p1/MAL-AK:MAL-BCC/ 
= 0.039; p2/ALA-AK:ALA-BCC/ = 0.63). MAL-PDT caused significantly 
less pain than ALA-PDT in both diagnosis groups (p3/MAL-AK:ALA-AK/ 
= 0.0083; p4/MAL-BCC:ALA-BCC/ = 0.00001).
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creasing age was associated with more pain sensation: 
significant difference was found between the 40–59 years 
and the > 80 years groups (one-way ANOVA, p = 0.008, 
Scheffe post hoc test, p40-59: > 80/ = 0.014).
No significant difference was observed between the 
different methods of pain relief: cooling the skin with 
wet gauze during treatment, oral analgesia, or both 
(one-way ANOVA, p = 0.77).
The two photosensitizers, ALA and MAL, were equally 
efficient (Table SI; available from http://www.medical-
journals.se/acta/content/?doi=10.2340/00015555-1223). 
DISCUSSION
PDT-associated pain is influenced by several intrinsic 
(patient-related) and extrinsic (treatment-related) factors. 
The anatomical region, the diagnosis and the size of the 
lesion, as well as the degree of photo-ageing, are signifi-
cant intrinsic determinants of treatment-related pain (3). 
Lesions on the scalp or forehead are more sensitive than 
those on the trunk and the extremities (4). Patients with 
AK seem to experience more intense pain than those with 
BCC (possibly due to more advanced photo-ageing), and, 
in general, pain increases with lesion size (4).
Extrinsic PDT factors, such as the use of analgesics, 
type of photosensitizer, light source, wavelength and 
dose, at least theoretically, provide the possibility to influ-
ence treatment-related pain. Several studies have reported 
attempts to moderate PDT-induced pain, but comparative 
investigations have not yet been performed. Cooling with 
wet gauze, thermal water spraying, and pre-treatment 
with capsaicin have also been tried, but with either no 
or limited effect (4). Pain of the most sensitive anatomi-
cal regions was successfully controlled by conduction 
anaesthesia (5). Cold air analgesia and subcutaneous 
local infiltrative anaesthesia, also proved valuable (6, 7). 
Nerve blocks provided effective pain relief during topical 
PDT (8). Pain can also be modulated through the choice 
of different light sources and wavelengths (9). 
MAL and ALA are the most widely used topical 
photosensitizers in the treatment of non-melanoma 
skin cancer. However, relatively few data are available 
concerning treatment-associated pain using the different 
photosensitizers. Kasche et al. (10) found that MAL-
PDT caused significantly less pain than did ALA-PDT 
in patients with multiple AKs on the scalp. The reason 
is probably the greater tumour selectivity of MAL or the 
fact that ALA, but not MAL, is actively transported to 
the peripheral nerve endings, triggering nerve stimula-
tion during its excitation (10). Steinbauer et al. (11) also 
considered the use of ALA, in contrast with MAL, as a 
factor predictive of higher PDT-associated pain.
In the present study, we evaluated treatment-associated 
pain during PDT of non-melanoma skin cancer in diffe-
rent anatomical regions, using the two photosensitizers, 
MAL and ALA. We found that, in the sensitive head 
region, MAL-PDT was more tolerable and caused signifi-
cantly less pain than ALA-PDT. There was a tendency for 
ALA-PDT to be more painful in all anatomical regions, 
but, in the case of the trunk and the extremities, the diffe-
rences were not significant. PDT of AK was significantly 
more painful than treatment of BCCs. Our findings are in 
accordance with previous studies as concerns the connec-
tion between the diagnosis and the therapy-induced pain. 
Moreover, the observed significant difference between 
MAL- and ALA-PDT associated pain in the BCC and 
AK groups, is in line with the previous observation that 
MAL-PDT causes less pain. 
Providing adequate pain relief during PDT presents 
difficulty. Our data confirm that, while ALA- and MAL-
PDT are similarly highly effective for the treatment of 
non-melanoma skin cancer, MAL-PDT is better tolera-
ted. The lower level of treatment-associated pain sug-
gests better suitability of MAL-PDT for the treatment 
of sensitive anatomical regions or for patients at risk of 
more pain (e.g. those with larger lesions, diagnosis of 
AK, photo-ageing or field cancerization). 
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